Adjuvant imatinib after resection of gastrointestinal stromal tumour - systematic review and meta-analysis
Journal Title: OncoReview - Year 2013, Vol 3, Issue 4
Abstract
[b]Background:[/b] Adjuvant therapy is recommended for population of patients with high risk of recurrence after resection of gastrointestinal stromal tumour.[b]The aim of the study:[/b] Evaluation of clinical efficacy and safety profile of imatinib used in adjuvant therapy in patients after complete resection of gastrointestinal stromal tumour.[b]Material and methods:[/b] A systematic review of literature published up to 30.03.2012 was performed and a meta-analysis of identified studies was carried out. Databases were searched: PubMed, EMBASE, The Cochrane Library and others.[b]Results:[/b] Two randomized clinical trials regarding comparisons of: imatinib vs. placebo and 12 months of adjuvant imatinib vs. 36 months of adjuvant imatinib as well as 20 non-randomized trials fulfilled established criteria. Adjuvant imatinib statistically significantly improves recurrence-free survival compared with placebo. Patients with high risk of recurrence benefit the most from assigned treatment. Three years of adjuvant imatinib therapy improve recurrence-free and overall survival compared with 1 year of imatinib in patients after resection of gastrointestinal stromal tumour. Safety profile of imatinib in analyzed population is acceptable.[b]Conclusions:[/b] For patients with a significant risk of recurrence adjuvant therapy with imatinib should be considered to each patient, due to the clinical benefits it brings.
Authors and Affiliations
Paweł Kawalec, Joanna Kryst, Tomasz Laczewski, Lech Martyna
Keywords
Related Articles
- EP ID EP67734
- DOI -
- Views 229
- Downloads 0
The management and outcome of essential thrombocythemia in pregnancy - single-center experience
Essential thrombocythemia (ET) is a myeloproliferative neoplasm characterized by an increase in platelet (PLT > 450 000/μl) and a tendency for either thrombosis or hemorrhage. ET is often diagnosed in elderly life...
Why does reimbursement of orphan drugs require a specific approach?
The greatest problem concerning the reimbursement of orphan products is their high price. In the case of orphan drugs, reimbursement and pricing decisions are highly interrelated. In decisions concerning reimbursement of...
Papillary renal cell carcinoma – case report of a patient with disseminated disease treated with pazopanib with several years of survival against reviewing current literature
Papillary renal cell carcinoma is the second most common histological type of renal cell carcinoma with distinct cytogenetics, histology and prognosis. It exhibits significantly poorer response to molecular targeted ther...
Dystres i depresja u chorych na nowotwory - diagnostyka i leczenie
Choroba nowotworowa burzy dotychczasowy porządek wewnętrzny i zewnętrzny pacjenta, który wcześniej nie przeżywał takiej sytuacji. Najczęściej odczuwanymi negatywnymi emocjami w sytuacji diagnozy onkologicznej są: lęk, pr...
The role of histopathological examination, therapeutic difficulties and thromboembolism treatment during palliative chemotherapy in patient with antithrombin deficiency , colon cancer and endometrial cancer
Palliative chemotherapy in patients with thrombophilia is a challenge for clinical oncologists. On one hand the optimal treatment should be very safe for patient, on the other hand – as effective as possible. That therap...